Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

The ECLIPSE Trial has completed enrollment with the randomization of 2000 patients. Dr. Philippe Généreux and I discuss the design of the trial in which vessel preparation strategies are compared in severely calcified coronary artery lesions.

CMichaelGibson's profile picture

C. Michael Gibson MD

430,270 subscribers

15,029 görüntüleme • 2 yıl önce •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

1 Yorum

David Bartov profil fotoğrafı
David Bartov2 yıl önce

@CardiacConsult Very informative interview, can’t wait to see the results.

Benzer Videolar

In the ShortCUT trial, the WOLVERINE™ Cutting Balloon delivers comparable safety, proven efficacy, and total procedural cost savings compared to current US market IVL for calcified coronary lesions. Explore the data: WOLVERINE™ Coronary Cutting Balloon™ Indications, Safety, and Warnings:
0:30

In the ShortCUT trial, the WOLVERINE™ Cutting Balloon delivers comparable safety, proven efficacy, and total procedural cost savings compared to current US market IVL for calcified coronary lesions. Explore the data: WOLVERINE™ Coronary Cutting Balloon™ Indications, Safety, and Warnings:

BostonSci Cardiology

13,488 görüntüleme • 4 ay önce

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:
1:20

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:

NEJM

16,263 görüntüleme • 7 ay önce

The #ECLIPSE trial presented by Ajay Kirtane at #TCT2024 showed that there was no difference between orbital atherectomy and POBA for severely calcified lesions. So I'm posting this clip from my four decades ago 1985 interview with Andreas Gruentzig about "The Ideal Catheter." He says: "For most of our problems at the present time, the balloon catheter is quite a good answer." #AngioHistory
2:16

The #ECLIPSE trial presented by Ajay Kirtane at #TCT2024 showed that there was no difference between orbital atherectomy and POBA for severely calcified lesions. So I'm posting this clip from my four decades ago 1985 interview with Andreas Gruentzig about "The Ideal Catheter." He says: "For most of our problems at the present time, the balloon catheter is quite a good answer." #AngioHistory

Angioplasty.Org

29,868 görüntüleme • 1 yıl önce

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:
1:24

The latest video in our partnership with Dr. Glaucomflecken summarizes the results of the VANISH2 trial, which compared catheter ablation versus antiarrhythmic drug therapy for ventricular tachycardia. View the full article for free:

NEJM

50,329 görüntüleme • 1 yıl önce

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:
1:28

In the latest video in our partnership with Dr. Glaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free:

NEJM

88,431 görüntüleme • 1 yıl önce

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:
1:17

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

NEJM

33,682 görüntüleme • 2 ay önce

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:
1:46

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,755 görüntüleme • 1 yıl önce

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.
1:30

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

NEJM

98,901 görüntüleme • 1 yıl önce

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:
1:39

Internal Medicine rounds are never “aggressively boring” with Dr. G. Watch the latest video in which Dr. Glaucomflecken summarizes the PICNIC trial. Access the article for free:

NEJM

92,522 görüntüleme • 1 yıl önce

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:
1:27

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

NEJM

89,732 görüntüleme • 5 ay önce

#BBCQuitIndia Okay Quitting today BJP and Modi should face trial in international court of Justice for #Godhra massacre and #GujaratRiots in which over 2000 minorities were killed with the help of state
0:25

#BBCQuitIndia Okay Quitting today BJP and Modi should face trial in international court of Justice for #Godhra massacre and #GujaratRiots in which over 2000 minorities were killed with the help of state

Anil Cherukara I.N.D.I.A

78,187 görüntüleme • 3 yıl önce

In preparation for the start of his public trial, the criminal Atef Najib appeared in the defendant’s dock before the #Criminal Court at the Palace of #Justice in #Damascus.
0:42

In preparation for the start of his public trial, the criminal Atef Najib appeared in the defendant’s dock before the #Criminal Court at the Palace of #Justice in #Damascus.

Qusay Noor

84,911 görüntüleme • 2 ay önce

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:
1:14

Our latest video in our partnership with Dr. Glaucomflecken summarizes a new trial investigating the mass administration of ivermectin for reducing malaria transmission. Read the full results of the BOHEMIA trial for free:

NEJM

19,398 görüntüleme • 7 ay önce

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:
0:58

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

NEJM

12,209 görüntüleme • 3 ay önce

Dr. Saibal Kar and Dr. C. Michael Gibson discuss the CHAMPION-AF trial: Left atrial appendage closure with the WATCHMAN FLX device was non-inferior to DOACs for the composite of CV death, stroke, or systemic embolism among patients with non-valvular AFib. #ACC26 Watch video here:
14:13

Dr. Saibal Kar and Dr. C. Michael Gibson discuss the CHAMPION-AF trial: Left atrial appendage closure with the WATCHMAN FLX device was non-inferior to DOACs for the composite of CV death, stroke, or systemic embolism among patients with non-valvular AFib. #ACC26 Watch video here:

C. Michael Gibson MD

10,732 görüntüleme • 3 ay önce

Ex-Minister Mohibul Hasan on Hasina verdict "Staged drama in the name of a trial. The whole process was illegal" Yunus turning "Bangladesh into a vessel state of ISI" "party which brought the country's freedom has been banned" Interview:
13:00

Ex-Minister Mohibul Hasan on Hasina verdict "Staged drama in the name of a trial. The whole process was illegal" Yunus turning "Bangladesh into a vessel state of ISI" "party which brought the country's freedom has been banned" Interview:

Sidhant Sibal

34,949 görüntüleme • 7 ay önce

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR
1:46

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR

PCRonline 🫀

31,014 görüntüleme • 3 yıl önce

For patients with generalized myasthenia gravis, existing treatments reduce mortality and alleviate symptoms, but side effects and poor efficacy leave many patients seeking alternatives. The latest video in our partnership with Dr. Glaucomflecken summarizes the MINT trial. 👉
1:40

For patients with generalized myasthenia gravis, existing treatments reduce mortality and alleviate symptoms, but side effects and poor efficacy leave many patients seeking alternatives. The latest video in our partnership with Dr. Glaucomflecken summarizes the MINT trial. 👉

NEJM

137,356 görüntüleme • 10 ay önce